Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin plus trabectedin combination therapy for leiomyosarcoma
jRCTs041250034Recruiting
- Start
- Jun 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of doxorubicin and trabectedin in leiomyosarcoma (LMS). Primary endpoint: Completion rate of 6 courses of doxorubicin + trabectedin therapy. Started Jun 2026; status: recruiting.
02
Drugs
doxorubicintrabectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on jRCTs041250034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250034.